University of Illinois at Chicago
Exemption #JDR392
Announcement of an Exempt Purchase
Award Info Published Wednesday November 13, 2024
Novartis Pharmaceutical CorporationEast Hanover, NJ
- Amount: An estimated $900,000
- Terms: An estimated start date of 11/8/2024 through 2/1/2025
- Renewals: None
Summary
Vendors
1 total
0 BEP vendors
0 VBP vendors
0 Small businesses
The University award process may be delayed as this award goes through a state approval process.
First published Wednesday, November 13, 2024
The University awarded a contract for radiopharmaceuticals.
This purchase is for the radiopharmaceuticals Pluvicto and Lutetium.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) Lutetium Lu-177 dotatate, is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The Pluvicto Lu-177 is indicated for the treatment for patients with Prostate Specific Membrane Antigen-Positive metastatic castration- resistant prostate cancer.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire qualified veterans, minorities, females, persons with disabilities and ex-offenders.